Finally, the prevalence rates for sarcopenia (33.6 vs. 48.0%) and severe sarcopenia (12.6 vs. 26.6%) were significantly (p < 0.05) reduced in the XOR inhibitor users. The gene discussed is XDH; the disease is sarcopenia.